BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu YH, Tsang JY, Ni YB, Hlaing T, Chan SK, Chan KF, Ko CW, Mujtaba SS, Tse GM. Doublecortin-like kinase 1 expression associates with breast cancer with neuroendocrine differentiation. Oncotarget. 2016;7:1464-1476. [PMID: 26621833 DOI: 10.18632/oncotarget.6386] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Deng H, Qianqian G, Ting J, Aimin Y. miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1. Biomedicine & Pharmacotherapy 2018;106:1072-81. [DOI: 10.1016/j.biopha.2018.07.024] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
2 Kadletz L, Thurnher D, Wiebringhaus R, Erovic BM, Kotowski U, Schneider S, Schmid R, Kenner L, Heiduschka G. Role of cancer stem-cell marker doublecortin-like kinase 1 in head and neck squamous cell carcinoma. Oral Oncology 2017;67:109-18. [DOI: 10.1016/j.oraloncology.2017.02.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
3 Kadletz L, Aumayr K, Heiduschka G, Schneider S, Enzenhofer E, Lill C. Overexpression of DCLK1 is predictive for recurrent disease in major salivary gland malignancies. Eur Arch Otorhinolaryngol. 2017;274:467-475. [PMID: 27470117 DOI: 10.1007/s00405-016-4227-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
4 Kang XL, He LR, Chen YL, Wang SB. Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis. World J Gastroenterol 2020; 26(43): 6853-6866 [PMID: 33268966 DOI: 10.3748/wjg.v26.i43.6853] [Reference Citation Analysis]
5 Harada Y, Kazama S, Morikawa T, Emoto S, Murono K, Kaneko M, Sasaki K, Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Hata K, Nozawa H, Ishihara S, Watanabe T. Prognostic impact of doublecortin-like kinase 1 expression in locally advanced rectal cancer treated with preoperative chemoradiotherapy. APMIS 2018;126:486-93. [DOI: 10.1111/apm.12852] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lai BS, Tsang JY, Poon IK, Shao Y, Chan SK, Tam FK, Cheung SY, Shea KH, Tse GM. The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas. Oncologist 2020;25:e1318-29. [PMID: 32472950 DOI: 10.1634/theoncologist.2020-0081] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
7 Lv Y, Song G, Wang R, Di L, Wang J. Doublecortin-like kinase 1 is a novel biomarker for prognosis and regulates growth and metastasis in basal-like breast cancer. Biomedicine & Pharmacotherapy 2017;88:1198-205. [DOI: 10.1016/j.biopha.2017.01.082] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
8 Yang WQ, Zhao WJ, Zhu LL, Xu SJ, Zhang XL, Liang Y, Ding XF, Kiselyov A, Chen G. XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression. Front Pharmacol 2021;12:603453. [PMID: 33762936 DOI: 10.3389/fphar.2021.603453] [Reference Citation Analysis]
9 Wang Y, Yi J, Liu X. Roles of Dclk1 in the pathogenesis, diagnosis, prognosis and treatment of pancreatic cancer: A review. Expert Rev Gastroenterol Hepatol 2021;:1-7. [PMID: 34937474 DOI: 10.1080/17474124.2022.2020643] [Reference Citation Analysis]
10 Krug K, Jaehnig EJ, Satpathy S, Blumenberg L, Karpova A, Anurag M, Miles G, Mertins P, Geffen Y, Tang LC, Heiman DI, Cao S, Maruvka YE, Lei JT, Huang C, Kothadia RB, Colaprico A, Birger C, Wang J, Dou Y, Wen B, Shi Z, Liao Y, Wiznerowicz M, Wyczalkowski MA, Chen XS, Kennedy JJ, Paulovich AG, Thiagarajan M, Kinsinger CR, Hiltke T, Boja ES, Mesri M, Robles AI, Rodriguez H, Westbrook TF, Ding L, Getz G, Clauser KR, Fenyö D, Ruggles KV, Zhang B, Mani DR, Carr SA, Ellis MJ, Gillette MA; Clinical Proteomic Tumor Analysis Consortium. Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell 2020;183:1436-1456.e31. [PMID: 33212010 DOI: 10.1016/j.cell.2020.10.036] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 14.5] [Reference Citation Analysis]
11 Liu H, Wen T, Zhou Y, Fan X, Du T, Gao T, Li L, Liu J, Yang L, Yao J, Ge Y, An G. DCLK1 Plays a Metastatic-Promoting Role in Human Breast Cancer Cells. Biomed Res Int 2019;2019:1061979. [PMID: 31223610 DOI: 10.1155/2019/1061979] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
12 Das CK, Linder B, Bonn F, Rothweiler F, Dikic I, Michaelis M, Cinatl J, Mandal M, Kögel D. BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells. Neoplasia 2018;20:263-79. [PMID: 29462756 DOI: 10.1016/j.neo.2018.01.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
13 Mohammadi Y, Tavangar SM, Saidijam M, Amini R, Etemadi K, Karimi Dermani F, Najafi R. DCLK1 plays an important role in colorectal cancer tumorgenesis through the regulation of miR-200c. Biomed Pharmacother 2018;103:301-7. [PMID: 29656186 DOI: 10.1016/j.biopha.2018.04.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
14 Dai T, Hu Y, Lv F, Ozawa T, Sun X, Huang J, Han X, Kishi H, Muraguchi A, Jin A. Analysis of the clinical significance of DCLK1+ colorectal cancer using novel monoclonal antibodies against DCLK1. Onco Targets Ther. 2018;11:5047-5057. [PMID: 30174443 DOI: 10.2147/ott.s169928] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
15 Ito S, Fujino Y, Ogata S, Hirayama-kurogi M, Ohtsuki S. Involvement of an Orphan Transporter, SLC22A18, in Cell Growth and Drug Resistance of Human Breast Cancer MCF7 Cells. Journal of Pharmaceutical Sciences 2018;107:3163-70. [DOI: 10.1016/j.xphs.2018.08.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
16 Dastmalchi N, Safaralizadeh R, Baradaran B, Hosseinpourfeizi M, Baghbanzadeh A. An update review of deregulated tumor suppressive microRNAs and their contribution in various molecular subtypes of breast cancer. Gene 2020;729:144301. [PMID: 31884105 DOI: 10.1016/j.gene.2019.144301] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
17 Shafiei S, Kalantari E, Saeednejad Zanjani L, Abolhasani M, Asadi Lari MH, Madjd Z. Increased expression of DCLK1, a novel putative CSC maker, is associated with tumor aggressiveness and worse disease-specific survival in patients with bladder carcinomas. Exp Mol Pathol 2019;108:164-72. [PMID: 31028726 DOI: 10.1016/j.yexmp.2019.04.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
18 Nishio K, Kimura K, Amano R, Nakata B, Yamazoe S, Ohira G, Miura K, Kametani N, Tanaka H, Muguruma K, Hirakawa K, Ohira M. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma. World J Gastroenterol 2017; 23(31): 5764-5772 [PMID: 28883702 DOI: 10.3748/wjg.v23.i31.5764] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
19 Westphalen CB, Quante M, Wang TC. Functional implication of Dclk1 and Dclk1-expressing cells in cancer. Small GTPases 2017;8:164-71. [PMID: 27458755 DOI: 10.1080/21541248.2016.1208792] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
20 Takiyama A, Tanaka T, Kazama S, Nagata H, Kawai K, Hata K, Otani K, Nishikawa T, Sasaki K, Kaneko M, Emoto S, Murono K, Takiyama H, Nozawa H. DCLK1 Expression in Colorectal Polyps Increases with the Severity of Dysplasia. In Vivo 2018;32:365-71. [PMID: 29475922 DOI: 10.21873/invivo.11247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Wang Z, Xia F, Labib M, Ahmadi M, Chen H, Das J, Ahmed SU, Angers S, Sargent EH, Kelley SO. Nanostructured Architectures Promote the Mesenchymal-Epithelial Transition for Invasive Cells. ACS Nano 2020;14:5324-36. [PMID: 32369335 DOI: 10.1021/acsnano.9b07350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
22 Shi W, Li F, Li S, Wang J, Wang Q, Yan X, Zhang Q, Chai L, Li M. Increased DCLK1 correlates with the malignant status and poor outcome in malignant tumors: a meta-analysis. Oncotarget 2017;8:100545-57. [PMID: 29246000 DOI: 10.18632/oncotarget.20129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
23 Tsang JY, Tse GM. Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification. Mod Pathol 2021;34:1062-73. [PMID: 33531618 DOI: 10.1038/s41379-021-00736-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zhang S, Zhang G, Guo H. DCAMKL1 is associated with the malignant status and poor outcome in bladder cancer. Tumour Biol 2017;39:1010428317703822. [PMID: 28621231 DOI: 10.1177/1010428317703822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
25 Agulto RL, Rogers MM, Tan TC, Ramkumar A, Downing AM, Bodin H, Castro J, Nowakowski DW, Ori-McKenney KM. Autoregulatory control of microtubule binding in doublecortin-like kinase 1. Elife 2021;10:e60126. [PMID: 34310279 DOI: 10.7554/eLife.60126] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Zhao S, Ma D, Xiao Y, Li XM, Ma JL, Zhang H, Xu XL, Lv H, Jiang WH, Yang WT, Jiang YZ, Zhang QY, Shao ZM. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. Oncologist 2020;25:e1481-91. [PMID: 32406563 DOI: 10.1634/theoncologist.2019-0982] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]